Revolutionizing Cell and Gene Therapy Delivery Through AI: A Supply Chain Perspective

Cell and gene therapies represent a revolutionary advancement in personalized medicine, offering unprecedented potential for treating previously incurable diseases through genetic modifications and cellular reprogramming. However, the complex manufacturing and distribution processes required for these therapies introduce significant challenges that conventional pharmaceutical supply chains are ill-equipped to handle. This article explores how artificial intelligence technologies are transforming the CGT supply chain, addressing critical challenges in manufacturing variability, production scheduling, quality control, and distribution logistics. By integrating machine learning algorithms, predictive analytics, and real-time monitoring systems, CGT manufacturers can enhance process control, optimize resource allocation, reduce product wastage, and ultimately improve patient outcomes. The integration of these complementary innovations creates new possibilities for overcoming longstanding barriers to CGT accessibility, affordability, and reliability, potentially accelerating the evolution of personalized medicine from an aspirational concept to a clinical reality for patients worldwide.